Trial Profile
Outcomes in patients with non small cell lung cancer treated with Erlotinib or Afatinib:a real world,retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jun 2017 New trial record
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.